ライフサイエンスコーパス: neurofibromatosis

1 rent orbital schwannoma without evidence for neurofibromatosis.

2 potential tumor suppressor with relevance to neurofibromatosis.

3 g to determine tumor burden in patients with neurofibromatosis.

4 nital, four were neuromuscular, and two were neurofibromatosis.

5 l uORF frameshift variant upstream of NF2 in neurofibromatosis.

6 nd most common neurocutaneous syndrome after neurofibromatosis.

7 in SDHB (n = 2), SDHD (n = 3), RET (n = 5), neurofibromatosis 1 (n = 1), and myc-associated factor X

8 negative Ras-MAPK-ERK regulator linked to a neurofibromatosis 1 (NF-1)-like human syndrome; however,

9 he phosphatase and tensin homolog (Pten) and neurofibromatosis 1 (Nf1) genes recently were found to b

10 arning to rut mutants, whereas expression of Neurofibromatosis 1 (NF1) in alpha/beta neurons is suffi

11 of children develop PA in the context of the neurofibromatosis 1 (NF1) inherited tumor predisposition

12 Neurofibromatosis 1 (NF1) is caused by mutations in the

13 Lack of expression of neurofibromin in neurofibromatosis 1 and its lethal derivative, malignant

14 Neurofibromatosis 1 is a hereditary syndrome characteriz

15 n EVH [Ena/Vasp homology] domain 1) and NF1 (neurofibromatosis 1) genes underlie clinically related h

16 yndrome, tuberous sclerosis complex 1 and 2, neurofibromatosis 1, phosphatase and tensin homolog, and

17 Children with neurofibromatosis-1 (NF1) are at risk for developing num

18 In this study, we used neurofibromatosis-1 (NF1) as a model system to elucidate

19 To study the role of the neurofibromatosis-1 (NF1) gene in mammalian brain develo

20 ious studies from our laboratories have used neurofibromatosis-1 (NF1) genetically engineered mouse (

21 ommon clinical problems in children with the neurofibromatosis-1 (NF1) inherited cancer syndrome.

22 s, T cells, and microglia interact to govern Neurofibromatosis-1 (NF1) low-grade glioma (LGG) growth.

23 In this regard, mutational inactivation of neurofibromatosis-1 (NF1), tuberous sclerosis complex (T

24 somal dominant human disorder that resembles Neurofibromatosis-1 (NF1).

25 ients and are a major contributing factor to neurofibromatosis-1 patient mortality and morbidity.

26 ession was also determined in KIT mutant and neurofibromatosis-1-associated GIST, and complex II acti

27 It is now known that neurofibromatosis-1-associated GISTs are SDHB-positive,

28 In patients with neurofibromatosis, 18F-FDG-PET demonstrated its applicat

29 the inherited cancer predisposition syndrome neurofibromatosis 2 (NF2) develop several central nervou

30 Merlin, encoded by the Neurofibromatosis 2 (NF2) gene, is a multifunctional tum

31 Inactivating mutations of the neurofibromatosis 2 (NF2) gene, NF2, result predominantl

32 Neurofibromatosis 2 (NF2) is an inherited cancer syndrom

33 hemotherapies, with ~50% showing loss of the Neurofibromatosis 2 (NF2) tumor suppressor gene.

34 We further show that the Neurofibromatosis 2 (Nf2) tumor suppressor inhibits Yap

35 Here we show that the tumor suppressor neurofibromatosis 2 (Nf2; merlin) limits the expansion o

36 er), a homolog of the human tumor suppressor neurofibromatosis 2, is required to coordinate prolifera

37 ion as a mediator of pathologies relevant to Neurofibromatosis 2.

38 The Neurofibromatosis-2 (NF2) tumor suppressor merlin negati

39 t not in N/S HNSTs arising in the context of neurofibromatosis (6 patients) or outside a tumor syndro

40 cause of extensive disfigurement from type 1 neurofibromatosis and 6 weeks after complete loss of his

41 These disorders, which include neurofibromatosis and Noonan and Legius syndromes, harbo

42 sus on the genetic and clinical diagnosis of neurofibromatosis and Proteus syndrome has allowed advan

43 sis Colorectal Cancer, Huntington's Disease, Neurofibromatosis and Sickle Cell Anaemia.

44 growth of neurofibromas in a mouse model of neurofibromatosis and that genetic and pharmacological i

45 Children with neurofibromatosis are reported separately.

46 s within the Department of Defense-sponsored Neurofibromatosis Clinical Trials Consortium.

47 multiple sclerosis, Guillain-Barre disease, neurofibromatosis, diseases of the neuromuscular junctio

48 Individuals with neurofibromatosis I (NF1) are at increased risk of devel

49 Von Recklinghausen neurofibromatosis is a common autosomal dominant genetic

50 Von Recklinghausen neurofibromatosis is caused by mutations in the NF1 gene

51 ling contributes to neurofibroma growth in a neurofibromatosis mouse model (Nf1(fl/fl);Dhh-Cre) or in

52 Neurofibromatosis (NF) encompasses a group of distinct g

53 1 (MEN1), von Hippel Lindau (VHL) syndrome, neurofibromatosis (NF-1), and possibly tuberous sclerosi

54 fiers of glioma risk in patients with type I neurofibromatosis (NF1) could help support personalized

55 Type I neurofibromatosis (NF1) is caused by mutations in the NF

56 It is not related to neurofibromatosis (NF1), nor is it associated with vascu

57 on the recent clinical insights into type I neurofibromatosis (NF1), the most common geno-oculo-derm

58 th disorders such as Legius syndrome, type 2 neurofibromatosis (NF2), and multiple lentigenes syndrom

59 usually occurring in individuals with type 2 neurofibromatosis (NF2).

60 stance commonly referred to as "orbitofacial neurofibromatosis" (OFNF).

61 We found that neurofibromatosis- or retinitis pigmentosa-causing mutat

62 targeted therapies have become a reality for neurofibromatosis patients, and hold substantial promise

63 esions in a cohort of 49 children with JMML, neurofibromatosis phenotype (and thereby NF1 mutation) w

64 This effort, known as the Neurofibromatosis Preclinical Consortium (NFPC), was est

65 the numerous growths that covered his body: neurofibromatosis, Proteus syndrome, and a combination o

66 dor Hospital presented disfigurements due to neurofibromatosis, severe burns, or ballistic trauma and

67 (male individuals only 30%; mixed sex 22%), neurofibromatosis type 1 (18%), Down's syndrome (16%), N

68 ccinate dehydrogenase B-D mutation (n = 21), neurofibromatosis type 1 (n = 1), RET (n = 1), no germli

69 edictors of outcome in patients with/without neurofibromatosis type 1 (NF-1) associated MPNST.

70 In neurofibromatosis type 1 (NF-1), malignant transformatio

71 Neurofibromatosis type 1 (NF1) and Legius syndrome are r

72 ances in our understanding of the biology of neurofibromatosis type 1 (NF1) and neurofibromatosis typ

73 Multiple tumors are a hallmark of neurofibromatosis type 1 (NF1) and type 2 (NF2) and schw

74 ifferent VA testing methods in children with neurofibromatosis type 1 (NF1) and/or optic pathway glio

75 Children with neurofibromatosis type 1 (NF1) are increasingly recogniz

76 Children with neurofibromatosis type 1 (NF1) are predisposed to juveni

77 Children with neurofibromatosis type 1 (NF1) are prone to learning and

78 th a broad range of signs typically found in neurofibromatosis type 1 (NF1) but no detectable NF1 ger

79 etermine the risk of cancer in patients with neurofibromatosis type 1 (NF1) by cancer type, age, and

80 Children with neurofibromatosis type 1 (NF1) cancer predisposition syn

81 Patients with neurofibromatosis type 1 (NF1) carry approximately a 10%

82 Patients with neurofibromatosis type 1 (NF1) develop benign plexiform

83 Children with neurofibromatosis type 1 (NF1) develop low-grade brain t

84 Individuals with neurofibromatosis type 1 (NF1) frequently exhibit cognit

85 The neurofibromatosis type 1 (Nf1) gene encodes a GTPase act

86 The neurofibromatosis type 1 (NF1) gene encodes the GTPase-a

87 In this review, we highlight advances in neurofibromatosis type 1 (NF1) genetically engineered mo

88 e imaging for an optic pathway glioma and/or neurofibromatosis type 1 (NF1) had multiple 6 x 6 mm vol

89 Persons with neurofibromatosis type 1 (NF1) have a predisposition for

90 found that loss of the tumor suppressor gene neurofibromatosis type 1 (Nf1) increased HSF1 levels and

91 from tumor cells, we demonstrate how loss of neurofibromatosis type 1 (NF1) increases RAS-GTP levels

92 mors (pilocytic astrocytomas) arising in the neurofibromatosis type 1 (NF1) inherited cancer predispo

93 Individuals with the neurofibromatosis type 1 (NF1) inherited cancer syndrome

94 Neurofibromatosis type 1 (NF1) is a common autosomal dom

95 Neurofibromatosis type 1 (NF1) is a common cancer predis

96 Neurofibromatosis type 1 (NF1) is a common cancer predis

97 Neurofibromatosis type 1 (NF1) is a common genetic disor

98 Neurofibromatosis type 1 (NF1) is a common genetic disor

99 Neurofibromatosis type 1 (NF1) is a common monogenic neu

100 Neurofibromatosis type 1 (NF1) is a common neurodevelopm

101 Neurofibromatosis type 1 (NF1) is a common neurodevelopm

102 Neurofibromatosis type 1 (NF1) is a common neurogenetic

103 Neurofibromatosis type 1 (NF1) is a common neurogenetic

104 Neurofibromatosis type 1 (NF1) is a common tumor predisp

105 Neurofibromatosis type 1 (NF1) is a common tumor-predisp

106 Neurofibromatosis type 1 (NF1) is a genetic disease that

107 Neurofibromatosis type 1 (NF1) is a genetic disorder res

108 Pulmonary hypertension (PH) associated with neurofibromatosis type 1 (NF1) is a rare and largely unk

109 Neurofibromatosis type 1 (NF1) is a rare, autosomal domi

110 Neurofibromatosis type 1 (NF1) is an autosomal dominant

111 Neurofibromatosis type 1 (NF1) is an autosomal dominant

112 Neurofibromatosis type 1 (NF1) is an inherited disease i

113 The diagnosis of neurofibromatosis type 1 (NF1) is based on 7 clinical cr

114 Neurofibromatosis type 1 (NF1) is the most common geneti

115 Neurofibromatosis type 1 (NF1) is the most common monoge

116 Neurofibromatosis type 1 (NF1) patients are predisposed

117 Neurofibromatosis type 1 (NF1) patients develop benign n

118 ival rates and the leading cause of death in neurofibromatosis type 1 (NF1) patients under 40 years o

119 e observation that half of MPNSTs develop in neurofibromatosis type 1 (NF1) patients, subsequent to N

120 f dysregulated miRs have not been studied in neurofibromatosis type 1 (NF1) plexiform neurofibromas (

121 Neurofibromatosis type 1 (NF1) predisposes individuals t

122 Neurofibromatosis type 1 (NF1) results from mutations in

123 Neurofibromatosis type 1 (NF1) results from mutations in

124 Vision, quality of life, neurofibromatosis type 1 (NF1) status, and BRAF mutation

125 roma to a malignant sarcoma in patients with neurofibromatosis type 1 (NF1) syndrome remains unclear.

126 (PN) tumors are a hallmark manifestation of neurofibromatosis type 1 (NF1) that arise in the Schwann

127 Mutations in the neurofibromatosis type 1 (NF1) tumor suppressor gene are

128 characterized by biallelic mutations in the neurofibromatosis type 1 (NF1) tumor suppressor gene.

129 neoplasms (SNs) in children with pathogenic neurofibromatosis type 1 (NF1) variants exposed to radia

130 TOPIC: Children and adults with neurofibromatosis type 1 (NF1), a common autosomal domin

131 Children and adults with neurofibromatosis type 1 (NF1), a common autosomal domin

132 tions in the NF1 tumor suppressor gene cause neurofibromatosis type 1 (NF1), a common genetic disorde

133 Neurofibromatosis type 1 (NF1), a common genetic disorde

134 ris) is one of seven diagnostic criteria for neurofibromatosis type 1 (NF1), a common monogenic disor

135 Neurofibromin gene (NF1) mutation causes neurofibromatosis type 1 (NF1), a disorder in which brai

136 y the NF1 gene, the mutation of which causes Neurofibromatosis type 1 (NF1), a genetic disorder chara

137 metastatic sarcomas that are associated with neurofibromatosis type 1 (NF1), a prominent inherited ge

138 sion profiles in iN cells from patients with neurofibromatosis type 1 (NF1), a single-gene multifacet

139 Neurofibromatosis type 1 (NF1), an NCFC syndrome, is cau

140 an important ocular finding in patients with neurofibromatosis type 1 (NF1), and early detection of t

141 n, in which loss-of-function mutations cause Neurofibromatosis Type 1 (NF1), contributes to the major

142 In neurofibromatosis type 1 (NF1), deregulation of Ras sign

143 on inherited cancer predisposition syndrome, neurofibromatosis type 1 (NF1), the prevalence of these

144 ging a genetically engineered mouse model of neurofibromatosis type 1 (NF1)-associated optic glioma,

145 This study reports on neurofibromatosis type 1 (NF1)-associated optic pathway

146 Stratum 3 comprised patients with any neurofibromatosis type 1 (NF1)-associated paediatric low

147 omas, OPGs), especially in children with the neurofibromatosis type 1 (NF1)-inherited tumor predispos

148 causing the genetic neurocutaneous disorder neurofibromatosis type 1 (NF1).

149 tions in the NF1 tumor suppressor gene cause Neurofibromatosis type 1 (NF1).

150 ur sporadically in a subset of patients with neurofibromatosis type 1 (NF1).

151 y-resistant tumours arising in patients with neurofibromatosis type 1 (NF1).

152 ng RAS activity via promoting degradation of neurofibromatosis type 1 (NF1).

153 rments are one of the many manifestations of neurofibromatosis type 1 (NF1).

154 and is mutated in humans with the condition neurofibromatosis type 1 (NF1).

155 comas that frequently arise in patients with neurofibromatosis type 1 (NF1).

156 te new treatments for tumors associated with neurofibromatosis type 1 (NF1).

157 oplasms that commonly occur in patients with neurofibromatosis type 1 (NF1).

158 ed autistic trait burden in individuals with neurofibromatosis type 1 (NF1).

159 auses substantial morbidity in patients with neurofibromatosis type 1 (NF1).

160 kin hyperpigmentation are early hallmarks of neurofibromatosis type 1 (NF1).

161 l feature of the common neurogenetic disease neurofibromatosis type 1 (NF1).

162 benign neurofibromas (BNFs) in patients with neurofibromatosis type 1 (NF1).

163 erlie the prevalent familial cancer syndrome neurofibromatosis type 1 [1].

164 Although many manifestations of neurofibromatosis type 1 affect the nervous system, othe

165 e sheath tumors often arise in patients with neurofibromatosis type 1 and are among the most treatmen

166 d, such as Angelman syndrome, Rett syndrome, Neurofibromatosis Type 1 and Fragile X syndrome, the cla

167 In this phase 2 trial, most children with neurofibromatosis type 1 and inoperable plexiform neurof

168 arly-phase data suggested that children with neurofibromatosis type 1 and inoperable plexiform neurof

169 PK kinase (MEK) 1 and 2, in children who had neurofibromatosis type 1 and inoperable plexiform neurof

170 dromic children, whereas 2 subtypes, JMML in neurofibromatosis type 1 and JMML in children with CBL s

171 ant signaling pathway that is deregulated in neurofibromatosis type 1 and malignant peripheral nerve

172 Children with neurofibromatosis type 1 and symptomatic inoperable plex

173 s in plexiform neurofibromas associated with neurofibromatosis type 1 and the use of Ras pathway inhi

174 initially thought to have NS was revised to neurofibromatosis type 1 based on an NF1 nonsense mutati

175 A. beta-catenin modulation in neurofibromatosis type 1 bone repair: therapeutic implic

176 the relative contribution of vision loss and neurofibromatosis type 1 co-diagnosis within a large sam

177 targeting the affected signaling pathways in neurofibromatosis type 1 for the treatment of cognitive

178 Neurofibromatosis type 1 is a relatively common inherite

179 Neurofibromatosis type 1 is a tumor-predisposing genetic

180 stages of development.SIGNIFICANCE STATEMENT Neurofibromatosis type 1 is associated with cognitive pr

181 Neurofibromatosis type 1 is due to a reduction of the tu

182 Neurofibromatosis type 1 is the most commonly inherited

183 On occasion, neurofibromas in neurofibromatosis type 1 may be present on the lid, brow

184 e, the association of clinical symptoms with neurofibromatosis type 1 might not be appreciated.

185 Neurofibromatosis type 1 results from autosomal dominant

186 years after CRT correlated with patient age, neurofibromatosis type 1 status, tumor location and volu

187 of Nf1, the Ras GTPase gene underlying human neurofibromatosis type 1 syndrome, causes lens dysgenesi

188 at occur sporadically or in association with neurofibromatosis type 1 syndrome.

189 ildren with an OPG (sporadic or secondary to neurofibromatosis type 1) who were cooperative for visua

190 n (phosphatase with tensin homolog) and Nf1 (neurofibromatosis type 1), enhanced filopodial motility.

191 n in the NF1 tumor suppressor gene underlies Neurofibromatosis type 1, a complex disease that enhance

192 enetics, and cancer screening guidelines for neurofibromatosis type 1, Beckwith-Wiedemann syndrome/ h

193 essor NF1 contributes to the pathobiology of neurofibromatosis type 1, but a related role has not bee

194 nd to provide optimum care for patients with neurofibromatosis type 1, clinicians must be aware of th

195 r muscles, lymphedema-distichiasis syndrome, neurofibromatosis type 1, congenital myasthenic syndrome

196 This study shows that, in a mouse model of neurofibromatosis type 1, cortical inhibition is increas

197 of neurofibromin 1 (Nf1), a gene mutated in neurofibromatosis type 1, unlocked a latent oligodendroc

198 asionally been described in association with neurofibromatosis type 1, whereas an association with ne

199 enotype is reminiscent of the human disorder neurofibromatosis type 1, which is characterized by disf

200 Studies of human neurofibromatosis type 1-associated tumors suggest that

201 Neurofibromatosis type 1-derived Schwann cells isolated

202 We report 4 cases of pediatric OPGs (2 neurofibromatosis type 1-related and 2 sporadic cases) t

203 so tested selumetinib using a mouse model of neurofibromatosis type 1-related neurofibroma.

204 l therapies are lacking for the treatment of neurofibromatosis type 1-related plexiform neurofibromas

205 onship to choroidal nodules in patients with neurofibromatosis type 1.

206 s) develop sporadically or in the context of neurofibromatosis type 1.

207 ble plexiform neurofibromas in patients with neurofibromatosis type 1.

208 the more common ophthalmic manifestations of neurofibromatosis type 1.

209 of cases, primarily in the optic nerve, with neurofibromatosis type 1.

210 r in association with the inherited syndrome neurofibromatosis type 1.

211 as a novel mechanism in the pathogenesis of neurofibromatosis type 1.

212 ith a heterozygous mutation of Nf1 linked to neurofibromatosis type 1.

213 e delay observed in patients with IBMPFD and neurofibromatosis type 1.

214 e plexiform neurofibroma microenvironment of neurofibromatosis type 1.

215 had prior chemotherapy, and 13 patients had neurofibromatosis type 1.

216 cur sporadically, after radiotherapy, and in neurofibromatosis type 1.

217 ng in approximately 35%-40% of patients with neurofibromatosis type 2 (NF2) and progressive vestibula

218 of the tumor suppressor NF2/merlin underlies neurofibromatosis type 2 (NF2) and some sporadic tumors.

219 iology of neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2) as they relate to the dev

220 INTRODUCTION: Patients with neurofibromatosis type 2 (NF2) develop bilateral cochleo

221 teral vestibular schwannomas associated with neurofibromatosis type 2 (NF2) experience significant mo

222 n the long arm of chromosome 22 and near the neurofibromatosis type 2 (NF2) gene (22q12) were most fr

223 Loss of function mutations in the neurofibromatosis Type 2 (NF2) gene, coding for a tumour

224 Neurofibromatosis type 2 (NF2) is a dominantly inherited

225 Neurofibromatosis type 2 (NF2) is a multiple neoplasia s

226 Neurofibromatosis type 2 (NF2) is a tumor predisposition

227 Neurofibromatosis type 2 (NF2) is an autosomal dominant

228 Neurofibromatosis type 2 (NF2) is an autosomal dominant

229 Neurofibromatosis type 2 (NF2) is an autosomal dominant

230 Neurofibromatosis type 2 (NF2) is an autosomal-dominant

231 Neurofibromatosis type 2 (NF2) is an autosomal-dominant

232 Neurofibromatosis type 2 (NF2) is an inherited disorder

233 Neurofibromatosis type 2 (NF2) is caused by mutations in

234 e patient suggests possible association with neurofibromatosis type 2 (NF2) or schwannomatosis.

235 The neurofibromatosis type 2 (NF2) tumor suppressor gene enc

236 Inactivation of the neurofibromatosis type 2 (NF2) tumor suppressor gene fun

237 ort here that liver-specific deletion of the neurofibromatosis type 2 (Nf2) tumor suppressor gene in

238 We previously identified the neurofibromatosis type 2 (NF2) tumor suppressor Merlin a

239 The neurofibromatosis type 2 (NF2) tumor suppressor, Merlin,

240 The neurofibromatosis type 2 (NF2) tumor-suppressor protein

241 vant targets, we examined the role of YAP in neurofibromatosis type 2 (NF2) using cell and animal mod

242 uirement for the PAKs in the pathogenesis of Neurofibromatosis type 2 (NF2), a dominantly inherited c

243 Neurofibromatosis type 2 (NF2), a dominantly inherited t

244 ions in the merlin tumor suppressor underlie neurofibromatosis type 2 (NF2), a familial autosomal dom

245 function mutations or deletions in NF2 cause neurofibromatosis type 2 (NF2), a multiple tumor forming

246 mutations underlie inherited tumor syndrome neurofibromatosis type 2 (NF2), as well as various spora

247 ene in a panel of 239 schwannoma tumours: 97 neurofibromatosis type 2 (NF2)-related schwannomas, 104

248 ed with increased mortality in patients with neurofibromatosis type 2 (NF2).

249 th germ line as well as somatic mutations in neurofibromatosis type 2 (NF2).

250 cally or as part of the hereditary condition neurofibromatosis Type 2 (NF2).

251 refers to an Italian 69 year old woman with neurofibromatosis type 2 and a pancreatic gastrinoma.

252 om 21 vestibular schwannomas associated with neurofibromatosis type 2 and from 22 sporadic schwannoma

253 Ten consecutive patients with neurofibromatosis type 2 and progressive vestibular schw

254 hearing in some, but not all, patients with neurofibromatosis type 2 and was associated with a reduc

255 is a tumor suppressor protein encoded by the neurofibromatosis type 2 gene NF2.

256 omatosis type 1, whereas an association with neurofibromatosis type 2 has never been reported.

257 Neurofibromatosis type 2 is an autosomal-dominant multip

258 Neurofibromatosis type 2 is an inherited autosomal disor

259 Neurofibromatosis type 2 is an inherited, neoplastic dis

260 lly and in the context of schwannomatosis or neurofibromatosis type 2 or 1.

261 Neurofibromatosis type 2 patients develop schwannomas, m

262 eral point mutants of Merlin associated with neurofibromatosis type 2 that display an aberrant phosph

263 The neurofibromatosis type 2 tumor suppressor protein, merli

264 hese actions of ezrin are antagonized by the neurofibromatosis type 2 tumor-suppressor protein merlin

265 examined from an additional 39 patients with neurofibromatosis type 2 who were retrospectively identi

266 erlin/NF2 (moesin-ezrin-radixin-like protein/neurofibromatosis type 2) is a tumor suppressor found to

267 In neurofibromatosis type 2, a dominantly inherited tumor d

268 nd hearing loss is a serious complication of neurofibromatosis type 2, a genetic condition associated

269 xternal ophthalmoplegia, myotonic dystrophy, neurofibromatosis type 2, and basal cell nevus syndrome.

270 taneously or as part of a hereditary disease neurofibromatosis type 2.

271 first case of coexistence of gastrinoma with neurofibromatosis type 2.

272 ation of schwannoma tumours in patients with neurofibromatosis type 2.

273 aracterized by abnormal vasculature, such as neurofibromatosis type 2.

274 y benign, and are frequently associated with neurofibromatosis type 2.

275 the remainder acquire a de novo mutation for neurofibromatosis type 2.

276 ical findings, and management strategies for neurofibromatosis type 2.

277 We also show that KIBRA associates with neurofibromatosis type 2/Merlin in a Ser(539) phosphoryl

278 Neurofibromatosis type I (NF-1), affecting 1: 3000 peopl

279 may occur sporadically, in association with neurofibromatosis type I (NF1 associated) or after radio

280 n tumors encountered in individuals with the neurofibromatosis type I (NF1) cancer predisposition syn

281 In this communication, we report that neurofibromatosis type I (NF1) exon 23a is a novel targe

282 Neurofibromatosis type I (NF1) is a genetic disorder cau

283 Neurofibromatosis type I (Nf1) is a GTPase-activating pr

284 Neurofibromatosis Type I (NF1) is a single-gene disorder

285 Neurofibromatosis type I (NF1) is an autosomal disorder

286 Neurofibromatosis type I (NF1) is characterized by promi

287 Neurofibromatosis type I (NF1) is one of the most common

288 Mutations in NF1 cause neurofibromatosis type I (NF1), a disorder characterized

289 Neurofibromatosis type I (NF1), caused by the mutation i

290 n a mouse model for learning disabilities in neurofibromatosis type I (NF1).

291 fragile X, Rett syndrome, Down syndrome, and neurofibromatosis type I suggest that it is possible to

292 ly member, regulates three target pre-mRNAs: neurofibromatosis type I, Fas and HuD.

293 Neurofibromatosis type II (NF2) is a disease that lacks

294 decades ago as a tumor suppressor underlying Neurofibromatosis type II, its precise molecular mechani

295 Individuals with neurofibromatosis type-1 (NF1) can manifest focal skelet

296 oradically or in patients with the inherited neurofibromatosis type-1 (NF1) syndrome.

297 mors (MPNST) develop in approximately 10% of neurofibromatosis type-1 patients and are a major contri

298 In humans, mutations in the NF2 gene cause neurofibromatosis type-2 (NF2), a cancer syndrome charac

299 ted tumor predisposition syndrome, including neurofibromatosis types 1 (NF1) and 2 (NF2), familial sc

300 t of a zebrafish model of von Recklinghausen neurofibromatosis will allow for structure-function anal